Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial
Intensive BP control cut 7-year all-cause dementia.
RR 0.85
95% CI 0.78-0.91
P<0.001
n=33,995
8.85% vs 10.55% at 7 years overall (4-year active + 3-year posttrial)
Key points
Context & question:To determine whether the blood pressure and cardiovascular benefits of a nonphysician community healthcare provider-led intensive blood pressure control program persist over 7 years, including a 3-year posttrial phase.
Methods & population:Cluster-randomized trial (326 villages 1:1); 4-y intervention + 3-y posttrial; 33,995 adults ≥40 y with hypertension in 326 villages of rural China; Nonphysician-led intensive BP control (<130/80 mmHg) vs usual care; 7 years overall (4-year active + 3-year posttrial) follow-up.
Finding & limits:At 7 years, blood pressure was 138.8/80.7 mm Hg in the intervention group versus 152.3/86.1 mm Hg in usual care, with achieving <130/80 mm Hg. Design limitations: The dementia result is not in the linked publication abstract, its denominators and ascertainment methods are not described, and 2,661 participants (7.8%) did not enter the posttrial follow-up (33,995 → 31,334).
The First Hospital of China Medical University, Shenyang
“Hypertension control remains poor globally, highlighting the need for scalable strategies in the primary-care setting. The improvements seen in randomized trials tend to attenuate after the active intervention ends. Implementation-based programs have shown promise, but evidence on their long-term effects has thus far been sparse, especially for the intensive BP-lowering target of less than 130/80 mm Hg that was the focus of their study.”
Practice take·Hypertension researcher, Tulane University
“The achieved separation in BP was greater than that reported in any other major trial, including the SPRINT, and the resultant prevention of CVD and all-cause mortality was remarkable. The trial provides a clear demonstration that a simple intervention that is well delivered is very effective and belies the need for individualization of antihypertensive therapy in most adults.”
Practice take·Physician, University of Mississippi Medical Center
“The efficacy of the CRHCP approach might not be limited to low-resource settings. It might also work in high-resource settings like the US, but only if the health care community embraces such a model.”
Practice take·Epidemiologist, Tulane University School of Public Health
“The effect of blood pressure reduction on cardiovascular disease was consistent between older and middle-aged individuals and between those at high risk for cardiovascular disease and not at high risk for cardiovascular disease.”
Open questions from this trial that would benefit from expert input.
Ask about this paper
Answers are grounded in this paper and cite their sources.
Full evidence
Why the trial, tables, limitations, PICO, abstract, media & sources
Why the trial?
Hypertension is a leading modifiable risk factor for dementia, yet randomised evidence that sustained, intensive blood pressure control lowers dementia risk was lacking. CRHCP's long-term follow-up addressed that question.
Does a nonphysician community healthcare provider-led intensive blood pressure management program reduce cardiovascular events in adults with hypertension?
View moreView less
Evidence details
What drove the result?
Outcome
Intensive BP
Usual care
All-cause dementia at 7 years Hot Line primary · adjusted RR 0.85 (95% CI 0.78–0.91; p<0.001); from the trial record, not the linked Circulation abstract
Intensive BP 8.85%
Usual care 10.55%
CVD composite (MI, stroke, HF hosp., CVD death) over 7 years HR 0.76 (95% CI 0.72–0.81; p<0.0001) · primary of the Circulation CVD analysis
Intensive BP 2.4%/person-yr
Usual care 3.0%/person-yr
BP <130/80 mmHg at 7 years Mean BP 138.8/80.7 vs 152.3/86.1 mmHg (difference −13.5/−5.4; p<0.0001)
Intensive BP 33.9%
Usual care 10.5%
Limitations & tradeoffs
Safety
Intensive control increased hypotension (RR 1.58, 95% CI 1.39–1.79) and mild hypokalemia (RR 1.38, 95% CI 1.23–1.56) over 7 years; per-arm counts not reported.
Design limitations
The dementia result is not in the linked publication abstract, its denominators and ascertainment methods are not described, and 2,661 participants (7.8%) did not enter the posttrial follow-up (33,995 → 31,334).
Representation
Cluster-randomized design in rural China with trial-supplied discounted/free drugs and provider incentives may limit generalizability.
Structured PICO
Does a nonphysician community healthcare provider-led intensive blood pressure management program reduce cardiovascular events in adults with hypertension?
PPopulation
33,995 adults aged ≥40 years with hypertension or high CVD risk from rural China, followed over a 7-year overall period.
IIntervention
Nonphysician community healthcare provider (NPCHP)-led intensive BP control program targeting BP <130/80 mm Hg. Included medication initiation/titration, coaching, discounted/free medications, and performance incentives during a 4-year active phase, followed by a 3-year posttrial phase of continued NPCHP care without the discounted medications or incentives.
CComparator
Usual care (local standard BP management throughout the 7-year period).
OOutcome
Composite of myocardial infarction, stroke, hospitalization for heart failure, and CVD death.composite endpoint
Main Result
Relative Risk0.85 (95% CI 0.78–0.91)
Absolute Event Rate8.85% vs 10.55%
p-valuep=<0.001
A nonphysician-led intensive blood pressure management program targeting <130/80 mm Hg provides sustained cardiovascular risk reduction over 7 years, even after the withdrawal of trial-specific financial incentives and discounted medications.
Where experts stand
Experts read CRHCP as practice-changing: intensive blood pressure control delivered by community health workers lowered dementia risk, and the investigators and commentators want the model scaled up.
The reaction is uniformly positive. Commentators call this the first convincing trial evidence that a strategy can prevent dementia, and they say a simple, well-delivered blood pressure program works. The open question is whether a model built in rural villages will carry over to high-resource health systems that would need to adopt it.
Agreement
Clinicians who commented see the intervention as a proven tool for dementia prevention that should now be used. Jones calls it the first definitive trial evidence of dementia risk reduction, and He says it should be widely adopted and scaled up.
2 clinicians say this directly
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Still unclear
Jones notes that the approach might also work in high-resource settings like the US, but only if health systems embrace the model. That has not been tested. Whelton's claim that most adults do not need individualized antihypertensive therapy goes beyond what the trial directly compared.
Implication
Intensive BP control cut all-cause dementia at 7 years (8.85% vs 10.55%; RR 0.85); supports scaling NPCHP-led intensive BP programs for both dementia and CVD prevention.
Abstract
BACKGROUND: Hypertension is the leading risk factor for cardiovascular disease (CVD) worldwide. Implementation-based blood pressure (BP) control programs improve BP control and reduce CVD risk, but whether their benefits persist after withdrawal of trial-supported intervention components remains uncertain, especially when intensive BP control is targeted. In CRHCP (China Rural Hypertension Control Project), a nonphysician community healthcare provider (NPCHP)–led program with the intensive target of <130/80 mm Hg reduced CVD risk during the 4-year active intervention period. We extended follow-up for an additional 3 years to assess BP control and CVD outcomes over the 7-year overall period and during the 3-year posttrial period. METHODS: CRHCP was a cluster-randomized controlled trial conducted in rural China. Eligible participants were ≥40 years of age with BP ≥140/90 mm Hg or ≥130/80 mm Hg if at high CVD risk or receiving antihypertensive treatment. We randomly assigned 326 villages 1:1 to NPCHP-led intensive BP control or usual care. During the 4-year intervention, trained NPCHPs initiated and titrated antihypertensive medications using a standardized protocol under primary care physician supervision and provided coaching on home BP monitoring, lifestyle modification, and medication adherence. The program also provided discounted or free antihypertensive medications, additional training, and performance incentives. Participants in the usual care group received local standard BP management throughout. During the 3-year posttrial period from years 4 to 7, intervention participants continued care with their original NPCHPs, with physician and hypertension specialist consultation available; discounted or free medications, additional training, and performance incentives were discontinued. The primary outcome was a composite of myocardial infarction, stroke, hospitalization for heart failure, and CVD death. Treatment effects were evaluated separately over the 7-year overall and 3-year posttrial periods with prespecified subgroup analyses. RESULTS: Between May 8 and November 28, 2018, 33 995 participants were enrolled; 31 334 entered the posttrial follow-up. At the end of the 7-year overall period, BP was 138.8/80.7 mm Hg in the intervention group versus 152.3/86.1 mm Hg in the usual care group (between-group difference, −13.5/−5.4 mm Hg; P <0.0001 for both systolic and diastolic BPs); percentage of the participants with BP <130/80 mm Hg was 33.9% versus 10.5% ( P <0.0001). During the 7-year overall period, the rate of composite CVD events was 2.4% versus 3.0% per person-year in the intervention and usual care groups, respectively (hazard ratio, 0.76 [95% CI, 0.72–0.81]; P <0.0001). During the 3-year posttrial period, the corresponding rates were 3.4% versus 4.2% per person-year (hazard ratio, 0.79 [95% CI, 0.73–0.85]; P <0.0001). Posttrial effects in CVD risk reduction were generally consistent across subgroups defined by baseline age, sex, education, and antihypertensive medication use. Over the 7-year overall period, the intervention group had higher risks of hypotension (risk ratio, 1.58 [95% CI, 1.39–1.79]) and mild hypokalemia (risk ratio, 1.38 [95% CI, 1.23–1.56]; P <0.001 for both). CONCLUSIONS: Multicomponent BP management strategy with a BP target <130/80 mm Hg led by NPCHPs achieved sustained BP control and reduced CVD risk during both the 7-year overall and 3-year posttrial periods. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03527719.
Cite This Study
Sun et al. (2026) conducted an RCT in Hypertension (n=33,995). NPCHP-led intensive BP control vs. Usual care was evaluated on All-cause dementia at 7 years (RR 0.85, 95% CI 0.78-0.91, p=<0.001). Intensive BP control cut all-cause dementia at 7 years versus usual care. Composite CVD events over 7 years were lower as well, but dementia is this Hot Line's primary.
